1. Scrip
  2. >>Business
  3. >>Deals

Numab's Pipeline To Benefit From Intarcia Licensing Its ND016

 
• By Sten Stovall

Privately held Swiss immunology and immuno-oncology specialist Numab Therapeutics has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics, and will use the proceeds to advance its own drug pipeline, its co-founder tells Scrip.

Nerve cells
Numab develops next-generation multispecific antibody-based immunotherapies • Source: Shutterstock

Numab Therapeutics AG of Switzerland will use the money generated from an in-licensing deal with Intarcia Therapeutics Inc. to fund its own early-stage proprietary pipeline of innovative antibody-based therapeutics, which it believes has huge commercial potential, the Swiss biotech's co-founder told Scrip. 

Founded in 2011, Numab has leveraged its next-generation multi-specific technology to create a pipeline of proprietary antibody-based programs, while also...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.